Overcoming Imatinib Resistance in HES/CEL: S116836 as a Next-Generation PDGFRα Tyrosine Kinase Inhibitor

Imatinib Resistance in HES/CEL: Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are rare hematologic malignancies frequently driven by the FIP1L1-PDGFRα fusion oncogene. Although the tyrosine kinase inhibitor imatinib has demonstrated remarkable clinical efficacy in FIP1L1-PDGFRα–positive patients, the emergence of resistance—most notably due to the T674I gatekeeper mutation—poses a significant therapeutic challenge. This article reviews preclinical evidence supporting S116836, a novel tyrosine kinase inhibitor designed to overcome imatinib resistance. S116836 potently inhibits both wild-type and T674I mutant PDGFRα, leading to suppression of key downstream signaling pathways, including STAT3, PI3K/AKT, and Erk1/2. Importantly, S116836 demonstrates strong antitumor activity in vitro and in xenograft models, while simultaneously inducing apoptosis through both intrinsic and extrinsic pathways. The upregulation of the proapoptotic protein Bim-EL via Erk1/2 inhibition highlights a mechanistic basis for its proapoptotic effects. Collectively, these findings position S116836 as a promising next-generation targeted therapy with the potential to address unmet clinical needs in patients with imatinib-resistant HES/CE

Clinical Challenge: Imatinib Resistance in FIP1L1-PDGFRα-Driven HES/CEL

Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) are rare hematologic disorders characterized by persistent eosinophilia and progressive organ damage. A major breakthrough in understanding these diseases came with the identification of the FIP1L1-PDGFRα fusion oncogene, which acts as a key driver in a molecularly defined subset of patients. This fusion results from a cryptic interstitial deletion on chromosome 4q12, leading to constitutive activation of platelet-derived growth factor receptor alpha (PDGFRα) and uncontrolled proliferation of eosinophilic cells.

The discovery of this oncogenic driver rapidly translated into clinical benefit. Imatinib, a first-generation tyrosine kinase inhibitor (TKI), demonstrated remarkable efficacy in FIP1L1-PDGFRα–positive HES/CEL patients, even at low doses. Most patients achieve rapid and durable hematologic and molecular remissions, making imatinib a standard-of-care therapy for this molecular subtype. Its success further validated the paradigm of targeted therapy in hematologic malignancies.

However, despite these favorable outcomes, acquired resistance to imatinib has emerged as a critical clinical challenge. Although relatively rare, imatinib resistance in HES/CEL is clinically significant due to the aggressive disease course once resistance develops. The most well-characterized mechanism involves the T674I point mutation in the PDGFRα kinase domain. This mutation alters the “gatekeeper” residue, preventing effective imatinib binding and rendering the drug ineffective. Notably, the PDGFRα T674I mutation is structurally and functionally analogous to the T315I mutation in BCR-ABL, which is notorious for conferring resistance in chronic myeloid leukemia.

Patients harboring the T674I mutation often exhibit rapid disease progression and limited treatment options, highlighting a substantial unmet medical need. Conventional chemotherapies offer minimal benefit and are associated with significant toxicity, while alternative TKIs frequently lack sufficient potency against the resistant mutant kinase. As a result, the development of novel tyrosine kinase inhibitors capable of overcoming imatinib resistance has become an urgent priority.

Understanding the molecular basis of resistance not only informs drug design but also guides precision medicine strategies for HES/CEL. Targeting mutant PDGFRα with next-generation inhibitors represents a promising approach to restoring disease control, improving patient outcomes, and extending the success of targeted therapies beyond first-line treatment.

S116836: A Novel Tyrosine Kinase Inhibitor Targeting Resistant PDGFRα

The emergence of imatinib resistance in FIP1L1-PDGFRα–driven hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) has underscored the urgent need for next-generation tyrosine kinase inhibitors (TKIs). While imatinib remains highly effective for most patients, the development of resistance—particularly due to the T674I gatekeeper mutation in PDGFRα—poses a significant therapeutic obstacle. This mutation disrupts the binding of imatinib to the kinase domain, resulting in continued oncogenic signaling and disease progression. Against this backdrop, the development of S116836 represents a strategic effort to overcome mutation-driven resistance at the molecular level.

S116836 is a newly synthesized small-molecule TKI designed to potently inhibit PDGFRα activity, including both the wild-type (WT) receptor and the imatinib-resistant T674I mutant. Unlike first-generation TKIs, which were optimized primarily for WT kinase inhibition, S116836 was developed with a focus on maintaining binding affinity and inhibitory potency despite structural alterations within the ATP-binding pocket of PDGFRα. This design strategy directly addresses the gatekeeper mutation that renders many existing TKIs ineffective.

Preclinical evaluations demonstrate that S116836 exhibits strong inhibitory activity against PDGFRα kinase function, positioning it as a promising candidate for resistant disease. Importantly, its activity is not limited to a single mutation state, suggesting broader therapeutic utility across different molecular contexts of FIP1L1-PDGFRα–positive neoplasms. This dual activity against WT and mutant forms is a critical advantage, as it may reduce the likelihood of clonal escape and treatment failure.

In comparison with imatinib and other early-generation TKIs, S116836 shows enhanced potency in cellular models harboring the T674I mutation. This finding is particularly significant given the clinical parallels between PDGFRα T674I and BCR-ABL T315I, the latter of which necessitated the development of specialized inhibitors such as ponatinib. By targeting resistant PDGFRα directly, S116836 follows a similar evolutionary trajectory in precision oncology—moving from broad-spectrum inhibition toward mutation-informed drug design.

Overall, S116836 exemplifies a rational approach to overcoming acquired resistance in targeted leukemia therapy. Its development reflects a growing emphasis on designing TKIs capable of neutralizing resistant oncogenic kinases while preserving efficacy against their wild-type counterparts. As resistance remains a central challenge in the long-term management of HES/CEL, novel agents like S116836 may play a pivotal role in expanding treatment options for patients who no longer benefit from first-line therapies.

Mechanistic Insights: Inhibition of PDGFRα Signaling Pathways by S116836

Aberrant activation of receptor tyrosine kinases is a central mechanism driving malignant transformation and disease progression in FIP1L1-PDGFRα–positive hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL). The FIP1L1-PDGFRα fusion protein exhibits constitutive kinase activity independent of ligand binding, leading to persistent activation of multiple downstream signaling cascades that promote uncontrolled cell proliferation, survival, and resistance to apoptosis. Targeting these signaling networks is therefore critical for effective therapeutic intervention, particularly in the context of tyrosine kinase inhibitor (TKI) resistance.

S116836 exerts its antitumor activity primarily through potent inhibition of PDGFRα kinase activity, resulting in broad suppression of downstream oncogenic signaling pathways. Preclinical studies demonstrate that treatment with S116836 markedly reduces phosphorylation of PDGFRα, effectively shutting down its constitutive signaling capacity in both wild-type and T674I mutant FIP1L1-PDGFRα–expressing cells. This upstream inhibition is a key mechanistic feature, as it prevents signal propagation through multiple survival and growth-promoting pathways simultaneously.

Among the most critical downstream targets affected by S116836 are the STAT3, PI3K/AKT, and Erk1/2 pathways. STAT3 is a transcription factor frequently activated in hematologic malignancies, where it regulates genes involved in proliferation, immune evasion, and resistance to cell death. By suppressing STAT3 phosphorylation, S116836 disrupts transcriptional programs that support leukemic cell survival. Similarly, inhibition of the PI3K/AKT pathway diminishes pro-survival signaling, sensitizing malignant cells to apoptotic cues.

The Erk1/2 (MAPK) pathway plays a dual role in cell proliferation and apoptosis regulation. Constitutive Erk1/2 activation downstream of PDGFRα contributes to unchecked cell cycle progression in HES/CEL. S116836-mediated inhibition of Erk1/2 not only impairs proliferative signaling but also triggers proapoptotic mechanisms. Notably, Erk1/2 suppression has been linked to the upregulation of the BH3-only protein Bim-EL, a key mediator of mitochondrial (intrinsic) apoptosis. This highlights how targeted kinase inhibition can indirectly activate cell death pathways through signaling rewiring.

Fig. 1 Mechanistic Inhibition of PDGFRα Signaling by S116836 in FIP1L1-PDGFRα–Driven Malignancies

Importantly, the ability of S116836 to simultaneously inhibit multiple PDGFRα-driven signaling axes distinguishes it from first-generation TKIs that lose efficacy against resistant mutants. By comprehensively blocking oncogenic signaling at both the receptor and downstream effector levels, S116836 demonstrates a mechanistic robustness that is essential for overcoming mutation-driven drug resistance. These insights underscore the therapeutic potential of S116836 as a next-generation TKI capable of restoring signaling control in resistant FIP1L1-PDGFRα–positive malignancies.

Antitumor Efficacy of S116836 In Vitro and In Vivo

Demonstrating robust antitumor activity in both cellular and animal models is a critical step in validating any novel tyrosine kinase inhibitor for further therapeutic development. In the case of S116836, preclinical studies provide compelling evidence of its efficacy against FIP1L1-PDGFRα–driven malignancies, including models that recapitulate imatinib-resistant disease. These findings are particularly relevant for hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL), where therapeutic options become severely limited once resistance emerges.

In vitro studies using neoplastic cell lines expressing either wild-type (WT) or T674I mutant FIP1L1-PDGFRα demonstrate that S116836 effectively suppresses cellular proliferation in a dose-dependent manner. Importantly, cells harboring the T674I mutation—known to confer high-level resistance to imatinib—remain highly sensitive to S116836 treatment. This contrasts sharply with first-generation tyrosine kinase inhibitors, which typically show minimal activity against the gatekeeper mutation. The growth-inhibitory effects of S116836 are closely correlated with its ability to block PDGFRα phosphorylation and downstream oncogenic signaling, confirming on-target activity at the cellular level.

Beyond proliferation assays, S116836 significantly reduces clonogenic survival, indicating a sustained impact on the long-term viability of FIP1L1-PDGFRα–expressing cells. These results suggest that the compound not only halts cell growth but also impairs the self-renewal capacity of malignant clones. Such properties are essential for preventing disease persistence and relapse, particularly in leukemic conditions driven by constitutively active kinases.

The antitumor potential of S116836 is further supported by in vivo studies using nude mouse xenograft models. In these experiments, mice implanted with FIP1L1-PDGFRα–expressing tumor cells exhibit marked tumor growth suppression upon treatment with S116836. This effect is observed in xenografts derived from both WT and T674I mutant cells, underscoring the compound’s effectiveness in resistant disease settings. Notably, S116836 treatment leads to significant reductions in tumor volume without causing substantial toxicity, suggesting a favorable therapeutic index.

Collectively, these in vitro and in vivo findings establish S116836 as a potent inhibitor of FIP1L1-PDGFRα–driven tumor growth. Its consistent efficacy across multiple experimental models strengthens the rationale for further preclinical optimization and potential clinical evaluation. For patients with HES/CEL who develop resistance to imatinib, agents like S116836 may offer a viable path toward renewed disease control and improved outcomes.

Apoptosis Induction and Therapeutic Implications for HES/CEL

One of the defining characteristics of effective anticancer therapies is their ability not only to inhibit tumor cell proliferation but also to actively induce programmed cell death. In FIP1L1-PDGFRα–driven hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL), constitutive kinase signaling promotes strong survival advantages and suppresses apoptotic pathways. The novel tyrosine kinase inhibitor S116836 addresses this challenge by triggering apoptosis through multiple, complementary mechanisms, thereby reinforcing its therapeutic potential in both imatinib-sensitive and imatinib-resistant disease settings.